

# Microfluidic affinity and ChIP-seq analyses converge on a conserved FOXP2-binding motif in chimp and human, which enables the detection of evolutionarily novel targets

Christopher S. Nelson<sup>1,\*</sup>, Chris K. Fuller<sup>1</sup>, Polly M. Fordyce<sup>1,2</sup>, Alexander L. Greninger<sup>1</sup>, Hao Li<sup>1,\*</sup> and Joseph L. DeRisi<sup>1,2,\*</sup>

<sup>1</sup>Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94131, USA and <sup>2</sup>Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA

Received January 10, 2013; Revised March 20, 2013; Accepted March 21, 2013

## ABSTRACT

The transcription factor forkhead box P2 (FOXP2) is believed to be important in the evolution of human speech. A mutation in its DNA-binding domain causes severe speech impairment. Humans have acquired two coding changes relative to the conserved mammalian sequence. Despite intense interest in FOXP2, it has remained an open question whether the human protein's DNA-binding specificity and chromatin localization are conserved. Previous *in vitro* and ChIP-chip studies have provided conflicting consensus sequences for the FOXP2-binding site. Using MITOMI 2.0 microfluidic affinity assays, we describe the binding site of FOXP2 and its affinity profile in base-specific detail for all substitutions of the strongest binding site. We find that human and chimp FOXP2 have similar binding sites that are distinct from previously suggested consensus binding sites. Additionally, through analysis of FOXP2 ChIP-seq data from cultured neurons, we find strong overrepresentation of a motif that matches our *in vitro* results and identifies a set of genes with FOXP2 binding sites. The FOXP2-binding sites tend to be conserved, yet we identified 38 instances of evolutionarily novel sites in humans. Combined, these data present a comprehensive portrait of FOXP2's-binding properties and imply that although its sequence specificity has been conserved, some of its genomic binding sites are newly evolved.

## INTRODUCTION

FOXP2 is a transcription factor of interest in the development and evolution of language in humans (1). Broad interest in FOXP2 began with the discovery of its linkage to autosomal dominant transmission of developmental verbal dyspraxia, a deficit of speech articulation, in the large KE family pedigree (2). The trait was linked to a locus on chromosome 7 and eventually to a single nucleotide (residue 553) residing in the DNA-binding domain of FOXP2, a member of the forkhead box family of sequence-specific DNA-binding proteins (2–6). Several unrelated cases having similar phenotypes were also identified and typically involved truncation events of the 3'-end of the FOXP2 open reading frame (ORF) (2,7). Affected individuals have normal intelligence and hearing but have jerky, dysfluent and disordered speech (8). FOXP2, therefore, offers an entry point into understanding the molecular underpinnings of the development of patterned syntactic speech.

Shortly after the KE phenotype was mapped to FOXP2, analysis of the gene's sequence conservation revealed an interesting evolutionary history, adding another dimension to its importance in human speech. The mammalian sequence is well conserved except for two mutations in the human lineage (T303N and N325S), both N-terminal to the Zn-finger domain (Figure 1). Conservation analysis revealed an enhanced non-synonymous substitution rate in the hominid lineage, consistent with recent selection (9). In support of this idea, researchers found that FOXP2 locus sequences from a diverse panel of human individuals contain an excess of high-frequency derived alleles and rare intronic alleles indicative of a selective sweep in human ancestors (10,11). Animal models expressing

\*To whom correspondence should be addressed. Tel: +1 224 213 0560; Email: Christopher.nelson@derisilab.ucsf.edu  
Correspondence may also be addressed to Hao Li. Tel: +1 415 502 8187; Fax: +1 415 514 2617; Email: haoli@genome.ucsf.edu  
Correspondence may also be addressed to Joseph L. DeRisi. Tel: +1 415 418 3059; Fax: +1 415 514 2617; Email: joe@derisilab.ucsf.edu

either mutant FOXP2 or lower levels of wild-type protein have borne out the involvement of FOXP2 in vocalization in mice and in zebra finches (12–14). These results suggest that in addition to its developmental role in speech, FOXP2 may have had an evolutionary role in speech and language.

Although there exist several possible paths for the molecular evolution of FOXP2 function between ancestral primates and humans, here we investigate the simple possibilities that the selected protein mutations in the human lineage could have altered FOXP2's-binding activity, driving novel targeting and functions; and/or that the genomic binding sites in humans could have changed, causing modulation of targeting strength and gain and loss of FOXP2-binding targets.

Evaluation of these possibilities would be aided by a thorough understanding of the FOXP2 affinity profile, yet there is surprisingly poor agreement over the identity of the FOXP2 DNA-binding motif (Table 1). This poor agreement may be due to either the use of different experimental techniques or reliance on previous candidate motifs identified through studies of related proteins (e.g. FOXP1 and FOXP3) (15–17). The lack of a consistent binding site model makes it difficult to predict targets by sequence analysis, which in turn complicates the task of defining evolutionarily novel target repertoires.

Here, we clarify FOXP2's target motif using recently developed microfluidic methods that measure binding affinity of proteins to a library of different DNA sequences (18,19). The resulting detailed binding site model reveals essentially identical affinity profiles for the chimp and human FOXP2 orthologs, suggesting that evolutionary differences between lineages did not involve distinct binding preferences. The derived FOXP2 motif is corroborated by an unbiased search for overrepresented motifs within FOXP2-bound ChIP-seq peaks. We find that most motif sites are conserved, and they tend to be near other transcription factor genes. However, we also find instances of evolutionarily novel FOXP2 target binding sites, including genes involved in synaptic

plasticity and neural development, suggesting that changes in *cis* regulation may underlie novel functions of FOXP2 in human language.


## MATERIALS AND METHODS

### Cloning, mutagenesis and expression

Full-length FOXP2 coding sequence was initially amplified from HeLa cDNA (primers designed to isoform 1 Ensembl record CCDS5760, included in [Supplementary Information](#)) and placed into a PCR2.1-topo vector. Point mutations in the derived clone were corrected by site-directed mutagenesis (20). The sequence was confirmed by Sanger sequencing and assembly with phred/phrap. Chimp and human mutant R553H FOXP2 coding versions were constructed by site-directed mutagenesis on this wild-type human plasmid. We removed the first 213 codons by PCR and added flanking promoter, polyA, and His tag sequences necessary for *in vitro* transcription/translation and MITOMI (see [Supplementary Information](#)). The truncation removed the long polyglutamine stretch at the beginning of the protein for improved expression and solubility (Figure 1). A similar truncation was previously used for electromobility shift assay (EMSA) studies (21), as polyglutamine stretches of >40 residues are associated with misfolding and aggregation (22,23). The PCR products were purified by Promega Wizard gel purification and concentrated via vacuum centrifugation to ~140 ng/μl. TnT<sup>®</sup> T7 coupled reticulocyte lysate kit from Promega with the addition of 10 μM ZnCl<sub>2</sub> was used to produce the protein of interest. We included 3 μl of Fluorotect Green BODIPY charged lysine tRNA in each 75 μl translation reaction for detection of the protein by fluorescence.

### MITOMI mold and device fabrication

MITOMI devices were made as described previously (18,19). Briefly, molds for devices were fabricated on



**Figure 1.** Schematic of FOXP2 domains and truncated construct used in MITOMI experiments showing C2H2 zinc-finger domain, leucine zipper domain, forkhead box DNA-binding domain and histidine repeat epitope tag (6xHis). Human lineage substitutions are at positions 303 and 325. The R553H mutation linked to verbal dyspraxia lies within the DNA-binding domain. A polyglutamine (polyQ) stretch was removed by truncation of the shaded region. We 6xHis-tagged the C-terminus for recruitment and retention on chip.

**Table 1.** Previously reported models of the FOXP2-binding site

Publication	Data type	System	Motif
Vernes <i>et al.</i> (2007)	ChIP-chip	SH-SY5Y cells overexpressing FOXP2	TCTTCGT
Vernes <i>et al.</i> (2008)	EMSA	<i>In vitro</i> binding to <i>CNTAP2</i> sequence	AATTTG
Enard <i>et al.</i> (2009)	Gene expression	Humanized mice	TATTTAT
Vernes <i>et al.</i> (2011)	ChIP-chip	Wild-type embryonic mice	ARKTAMYT

4-inch silicon wafers by mask photolithography. Masks were based on previously published designs (18). The two layers of the device were made from RTV615 PDMS casts from the silicon molds. After partial curing, the two layers were aligned and baked. The two-layer device was then aligned and bonded to an epoxy-silane glass substrate (CEL associates) with a printed array of the DNA library. Finished devices were run as described previously (18,19,24).

### DNA library design, synthesis and printing

The full 740 oligonucleotide pseudorandom library was designed with software from Eisen and Mintseris (25) to include all possible 65 536 8-bp DNA sequences in a relatively compact sequence space. This minimal string was then divided into 52mer oligonucleotides. We ordered these single-stranded oligonucleotides with a 3' 14-base adapter sequence to enable synthesis of the complementary strand (IDT Coralville, IA, USA, [Supplementary Table S1](#)). A common labeled primer complementary to the common adapter (Alexa647-GTCATACCGCCGGA) was also ordered from IDT (Coralville, IA, USA). The second strand was synthesized with Klenow  $exo^-$  enzyme. For the targeted systematic mutation libraries, double-stranded oligonucleotides were synthesized by the same process and then serially diluted to final working concentrations of 0.001–2  $\mu$ M DNA. Printing was carried out with silicon tips on a contact printer. Libraries were resuspended to a final concentration of 3 $\times$  saline-sodium citrate buffer, with 0.125% polyethylene glycol-6000 (Fluka) and 12.5 mg/ml of D-(+)-trehalose dihydrate (Fluka).

### MITOMI data analysis

In general, we followed the analysis protocol described previously (19). An array of DNA chambers holding the library of double-stranded oligonucleotides was situated next to an array of 'button valves' that trap the interaction between each oligonucleotide sample and the protein of interest. At the end of each experiment, devices were scanned to measure fluorescence intensities using an arrayWoRx scanner with arrayWoRx 3.0.3 software suite release 1. Fluorescence data for bound DNA and protein at the button valve and free DNA in the DNA chamber were extracted from the scanned devices with Genepix 6.1.

To identify initial IUPAC motifs preferred by FOXp2, we used fREDUCE software to screen all degenerate Nmers in the sequence library for their Pearson correlation to associated binding scores (26). Using ratios of bound DNA signal to protein signal at the button valve, fREDUCE was run to identify preferred 6mers through 9mers with up to three degenerate positions. The bound DNA/protein ratio data were normalized to the highest observed ratio (displayed as "rNN") in all analyses except for comparison of binding strengths between wild-type and mutant constructs. The top scoring IUPAC sequences by correlation and *P*-value with respect to the whole data set were then used as input

'seeds' for MatrixREDUCE. Given a seed sequence, MatrixREDUCE searches for a local optimum position-specific affinity matrix (PSAM) that best fits the measured binding data (27). MatrixREDUCE was also run on all the random library-binding data without any initial seed sequence, to remove any potential for bias introduced by the constraints of the IUPAC motif representation. MatrixREDUCE results were then scored against the whole data set by Pearson's correlation between the observed and expected occupancies. PSAM motif logos were made with AffinityLogo software (27).

Binding curves were fit to a hyperbolic saturation curve with global non-linear regression in Graphpad Prism 4.00. A dilution series of the fluorescently labeled primer was used as a standard curve to calibrate the relationship between fluorescence intensity and free DNA concentration on the devices.

### Chromatin IP data

Processed ChIP-seq data from the Myers laboratory at Hudson Alpha were downloaded from the ENCODE portal of the UCSC Genome Browser (<http://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg18&g=wgEncodeHaibTfbs>). The data were derived from chromatin immunoprecipitation libraries from PFSK-1 and SK-N-MC cells using an antibody that recognizes the C-terminal 127 amino acids of FOXp2 (28). Cross-linked and sheared chromatin samples were sequenced and compared with libraries prepared without any immunoprecipitation. We used the peaks called by the Myers laboratory using QuEST, which collapses ChIP-seq signal from both strands of DNA and then calculates a fold enrichment of the peaks over the no immunoprecipitation control (29). There were two biological replicates from each cell line. We used the function `findOverlappingPeaks` in the R Bioconductor `ChIPpeakAnno` package (<http://www.bioconductor.org/packages/release/bioc/html/ChIPpeakAnno.html>) to first merge the replicate peaks within data from each cell line to form a set of 1483 peaks. For convenience, we will refer to the overlapping peak set of 1483 as 'replicate peaks'. We merged these replicate peaks to form a set of 71 high-confidence peak sequences that gave strong signals across all samples from both cell lines. The peaks' positions relative to the nearest genes, regardless of gene orientation, were annotated using the `annotatePeakInBatch` function of `ChIPpeakAnno` for genome build NCBI36. We determined GO term enrichment using the `getEnrichedGO` function of `ChIPpeakAnno` with maximum *P*-value of 0.05 after adjusting for multiple testing (30).

### Motif searching in ChIP-seq peaks

For the set of 1483 replicate peaks and the set of 71 high-confidence peaks, we extracted the genomic sequences plus 50 or 200 extra nucleotides on each end of the full peak sequence. These sequences were passed to MEME version 4.3.0, which output PWMs ranked by their E-values for representation in the set of positive sequences (31). The input parameters specified a minimum motif width of 8 bp,



a maximum motif width of 50 bp, a minimum of two sites and an E-value threshold of  $1 \text{ E-}50$ .

We also used the MITOMI-derived 7mer PSAM to score motifs within the 71 high-confidence peaks. For this analysis, we calculated the predicted occupancy ratio relative to the strongest sequence for 7mer windows across the entire oligonucleotide sequence (27) and then compared the score for the highest scoring window with the distribution of scores for all 7mers. We identified candidate target sites of interest by using a score threshold of 0.06, which returns the top 0.1% of 7mer scores.

### Conservation analysis

We hypothesized that FOXP2 motifs inside the ChIP-seq high-confidence peaks would exhibit elevated conservation relative to the surrounding sequence. Using the best PWM from our MEME analysis, we searched replicate peak regions for FOXP2-binding sites using TAMO v1.0 (32) to identify predicted binding sites. We selected a threshold of 90% of the maximum bit score to yield approximately one FOXP2 motif per ChIP-seq peak. The same approach was taken for the 71 high-confidence peaks and the larger list of 1483 replicate peaks. From 1483 peaks, we identified 472 that contained at least one instance of a FOXP2 motif within our 90% of maximum score threshold as scored by TAMO. We then determined conservation scores for windows extending 100-bp upstream and downstream of each predicted binding site using the UCSC phastCons44WayPrimate alignment score file (<http://hgdownload.cse.ucsc.edu/goldenpath/hg18/phastCons44way/primates/>). We used these to compute both an ensemble average of conservation and the principal components of conservation (using the R *prcomp* package) in the region centered on each predicted transcription factor-binding site (TFBS).

To find novel FOXP2-binding targets among the human ChIP-seq peaks, we searched the merged replicate peaks that had strong binding sites. Of these, 38 contained sites with a substantial reduction in predicted FOXP2 affinity (50% or less of maximum bit score) between human and chimp sequences. By analyzing the UCSC multiz44way alignment (<http://hgdownload.cse.ucsc.edu/goldenPath/hg18/multiz44way/>) of these 38 sites across human, chimp, gorilla, rhesus, marmoset, tarsier, mouse lemur and bushbaby, we identified 22 sites for which the changes are unique to the human lineage.

## RESULTS

### Human R553H mutant shows no binding activity

Previous EMSA studies did not detect binding of the R553H mutant to SV40 DNA sequence (21). These results are consistent with two possibilities: the mutant could lack DNA-binding activity, or the mutant could have altered target site specificity. To distinguish between these possibilities, we used a microfluidic-binding assay (MITOMI 2.0) to search for binding interactions between the mutant protein and a DNA library containing all possible 8-bp sequences. In brief, MITOMI


2.0 experiments measure affinities between a single BODIPY-labeled transcription factor and many Alexa-647 or Cy5-labeled DNA sequences in parallel; the measured DNA signal intensity normalized by the protein signal intensity provides a measure of the fractional protein occupancy at a given DNA concentration. Truncated human R553H protein gives essentially zero protein occupancy signal for all assayed sequences (Figure 2A). Our data, therefore, suggest that R553H has lost all DNA-binding activity and not just the ability to bind its normal motif.

### Chimp and human proteins produce similar patterns of binding

In contrast to the R553H mutant, the protein occupancy signal distribution for truncated chimp and human FOXP2 proteins contains a tail indicative of strong binding to a subset of DNA sequences (Figure 2A). Comparing the binding pattern of chimp and human truncated FOXP2 protein, it is clear that some probes are repeatedly bound, e.g. oligonucleotide #175, whereas most oligonucleotides exhibit low binding (Figure 2A and B). The binding patterns for the two proteins are similar (Pearson's  $r^2$  of 0.85, Figure 2B).

### Chimp and human orthologs bind similar motifs

Identifying the preferred motif that correlates with binding to the library of DNA sequences requires analysis because each 52-bp oligonucleotide contains many potential binding sites (19). To identify these target sites, we first used *fREDUCE*, which identifies preferred motifs based on the correlation between measured binding intensity and the presence of subsequences within each oligonucleotide and searched for preferred motifs between six and nine nucleotides in length (26). *fREDUCE* returns lists of degenerate consensus sequences ranked by their correlation to the observed pattern of binding to the DNA library. To determine the effects of nucleotide substitutions at each position within these target sites, we subsequently used *MatrixREDUCE*, which fits a local optimum PSAM to the observed pattern of binding (27). [Supplementary Table S2](#) lists preferred sequences obtained from analysis of four aggregated experiments for each protein ([Supplementary Table S3](#) lists predictions from individual experiments). As expected, the similar binding patterns observed for the chimp and human proteins produce similar enriched motifs (Figure 2C and D and [Supplementary Table S2](#)) ([Supplementary Figure S1](#) shows similar results obtained through *MatrixREDUCE* queries without an initial IUPAC seed sequence). The top motifs of different lengths are essentially nested versions of the same motif for the human and chimp protein, each containing a core TGTTKAC sequence. In summary, the chimp and human FOXP2 bind similar DNA oligonucleotides in our library and seem to prefer similar motifs.




**Figure 2.** Results from FOXP2 MITOMI 2.0 binding assays against a pseudorandom 8mer library. (A) Histograms of MITOMI data showing the ratios of DNA signal intensities to protein signal intensities for human R553H mutant, human WT and chimpanzee alleles. R553H shows no binding to any sequence in the library, whereas chimp and human FOXP2 produces strong binding to a subset of oligonucleotides. (B) Comparison of chimp and human binding ratios (rNN) for all oligonucleotides in the DNA library. Oligonucleotide #175 (used for later targeted analysis) is labeled in red. (C) Top scoring human MatrixREDUCE 7mer affinity logo generated using AffinityLogo (27). The height of each letter depicts the predicted energetic cost or benefit ( $\Delta\Delta G/RT$ ) of a particular nucleotide at that position in the motif. The centerline indicates zero energetic change. (D) Top scoring chimp MatrixREDUCE 7mer affinity logo.

### Systematic mutation of the binding motif provides base-specific affinity information

To experimentally confirm our prediction that chimp and human FOXP2-binding preferences are the same at the single-nucleotide level, and to explore the effects of flanking nucleotides on affinity, we measured affinities for FOXP2 constructs interacting with a series of oligonucleotides containing single-nucleotide substitutions. For this targeted binding curve library, we chose to use the 13bp containing a candidate high-affinity binding site within a strongly bound oligonucleotide (#175) as a reference sequence. We then designed 39 DNA sequences with all possible point mutations of this 13bp sequence within the context of the larger unchanged oligonucleotide (full DNA sequences in Supplementary Table S4). We

programmed the MITOMI device with a dilution series of each oligonucleotide and measured FOXP2 binding over the series. These experiments allowed us to calculate apparent  $K_a$ s by non-linear regression of the binding curves for all oligonucleotides (18).

Figure 3A plots the fold change in the  $K_a$ s for each motif variant for both truncated chimp and human versions of FOXP2 derived from analysis of individual binding curves (example curves for all oligonucleotides are shown in Supplementary Figures S2 and S3). The bulk of the sequence specificity lies in a 7-bp core motif, with relatively minor contributions outside of that core. Although a number of point variants (e.g. TATTTAC and TGTTTAT) are permissible for binding, with  $K_a$ s only 3-fold lower than the strongest sequence, other point



**Figure 3.** Affinity measurements for systematic mutations of the binding site and flanking sequences. (A) Fold change in affinity (mutated  $K_a$ /unmutated  $K_a$ ) shown in log-scale. At every position, three values are shown for substitutions with each alternate base relative to the starting sequence. Error bars represent the standard error of the mean. Chimp and human data are displayed in red and blue, respectively. (B) PSAM affinity logo based on the affinities displayed in part A for the human allele. As in Figure 2, the height of each of four base letters depicts the measured energetic cost or benefit ( $\Delta\Delta G/RT$ ) of adding that base at that position in the motif. The centerline indicates zero energetic change. (C) PSAM affinity logo based on the affinities displayed in part A for the chimp allele.

variants (e.g. TGTTAAC) are clearly disfavored, with  $K_a$ s  $>100$ -fold lower than the strongest sequence. Taking these measurements together, we constructed an improved position-specific affinity matrix (PSAM) that reflects the experimentally observed effects of each point mutation at each position (Figure 3B and C) (PSAM matrices are displayed in Supplementary Table S5).


In agreement with the pseudorandom library measurements, we find that the pattern of affinity is similar across the two proteins (Student's *t*-test on the mean and standard deviation of the separate experiments,  $P > 0.05$ ), confirming that there is essentially no difference in binding preferences between species. In addition, these derived motifs are in agreement with the motifs obtained via pseudorandom library measurements, except for slightly less G/T degeneracy at the fifth position in the 7mer. These motifs represent the most detailed *in vitro* description of the specificities of the FOXP2-binding sites to date and are distinct from all previously reported FOXP2-binding motifs (Table 1).

#### MITOMI results match an independently derived FOXP2 motif from ChIP-seq data

In parallel with our MITOMI efforts, we analyzed *in vivo* FOXP2 DNA-binding data from human neuronal cell

lines from the Myers laboratory released to the public as part of the ENCODE consortium (28,33). To study only the most reproducible ChIP-seq signal enrichment peaks, we first identified overlapping ChIP-seq signal peaks within the biological replicates for each cell line, yielding 1238 overlapping peaks (of 5111 peaks) for the PFSK1 cells, and 316 overlapping peaks (of 615 peaks) for the SK-N-MC cells. As noted in the 'Materials and Methods' section, we will refer to this overlapping peak set as 'replicate peaks'. Next, we narrowed this set to consider only those peaks that were shared between cell lines, yielding 71 high-confidence peaks.

To these 71 high-confidence ChIP-seq peaks, we added 50 bp of the flanking genomic sequence and searched for enriched sequence motifs using MEME (31). The resulting top position weight matrix [E-value =  $4.5E-82$ , relative entropy 13.7 bits (34)] is similar to the motif found using our MITOMI device (motif matrix logo Figure 4A, compare with Figure 3B). Extending our search set to all replicate peaks within each cell line generated similar results (Supplementary Figure S4). When including a wider sequence window of 200 bp around each peak, MEME returned 73 instances of a similar motif (E-value =  $2.6E-51$ ), but also identified 55 instances of a long putative homopolymer G/C stretch



**Figure 4.** FOXP2 target-binding motif as revealed by ChIP-seq analysis. (A) Motif derived from MEME analysis of 71 ChIP-seq peak sequences with 50 bp of flanking sequence included. Motifs are displayed with small sample correction error bars. (B) Histogram of the relative positioning of the 71 FOXP2 ChIP-seq sites relative to the start of the nearest neighboring gene.

(E-value =  $2.4E-56$ , Supplementary Figure S5). Among all high-confidence peaks, 47/71 (63%) contained at least one instance of our strongest predicted motif string, and 65/71 (92%) peaks contained a local PSAM motif score within the top 0.1% of all possible 7mers (Table 2 and Supplementary Table S6).

#### FOXP2 ChIP-seq peaks have a stereotyped position and flanking sequence bias

To better understand the regulatory relevance of these candidate FOXP2 sites, we investigated their location relative to nearby genes. The FOXP2 sites tend to cluster near the start of the closest gene model, with over half of the ChIP peaks occurring within 1 kb of a transcriptional start site (TSS) (Figure 4B and Supplementary Figure S6). Additionally, nucleotide bias calculations across the regions flanking the FOXP2-binding site revealed a G/C

bias on both sides of the FOXP2 motif instance (Supplementary Figure S7). This might explain the low information content G/C biased sequences identified in our MEME searches over the region surrounding ChIP-seq peaks (Supplementary Figure S5).

#### Characterization of predicted FOXP2 target genes

To functionally characterize these sites, we mapped nearby genes. Fifty-eight genes are within 5 kb of the 71 high-confidence ChIP sites, and 1049 annotated genes are within 5 kb of the replicate ChIP sites (Table 2 and Supplementary Table S7). Bioconductor GO term querying of these nearby genes returned several terms relating to other transcriptional regulators with strong *P*-values, suggesting that FOXP2 tends to target other transcription factor genes (Tables 3 and Supplementary Table S6). Genes near FOXP2 sites in the list that fit this description are *ZBTB16*, *NFIA*, *TBL1X*, *ZNF395*, *CITED2*, *JUNB*, *CBX7*, *FOXP1*, *FOXP2*, *FOXP3*, *NR3C1* (glucocorticoid receptor) and *FOXP2* itself. A binding site near the FOXP2 gene is nearest to the start of the non-coding *FOXP2* transcript NR\_033766.1, annotated as a candidate for nonsense-mediated decay. The enrichment of transcription factors in FOXP2's putative target repertoire suggests that FOXP2 could act as a master regulator during development.

Beyond our unbiased target search sets, we searched for FOXP2 ChIP-seq peaks upstream of candidate targets, including previously suggested binding partners that we did not detect in our higher stringency list. Potential interacting forkhead box proteins *FOXP4* and *FOXP2* are the closest annotated genes to two intergenic peaks 13–14 kb upstream with conserved strong matches to our motif (35). In addition, *HDAC2*, encoding a histone deacetylase that interacts with FOXP2 (35), has two upstream peaks. We find two strong FOXP2 localization peaks within intronic sequence of the gene that encodes CTBP1, which complexes with FOXP2 in yeast two-hybrid and co-immunoprecipitation assays (36). However, the genes for *NFATC2*, *GATAD2B*, *SFTPC*, *CC10* and *IL6* (35,37) encoding other annotated targets or binding partners have no strong FOXP2 ChIP-seq peaks. Overall, these data suggest that FOXP2 may engage in feedback regulation of several of its annotated binding partners.

#### Sequence conservation at FOXP2 localization peaks

We expected a high degree of conservation for functionally important elements within ChIP-seq peak regions. Using the NCBI36 UCSC phyloP scores for site-specific conservation of multiple aligned sequences (38), we observe that 51 of our 71 high-confidence peaks overlap well-conserved loci. Likewise, the average of aligned phastCons scores (39) reveals an increase in conservation centered on the predicted FOXP2-binding sites, as does the first principle component of the phastCons scores (Figure 5). This pattern holds true if we extend our analysis to the 472 replicate peaks that contain a motif scoring within 90% of the top motif PWM score (Supplementary Figure S8). Such elevated conservation further suggests the motif we identified is evolutionarily



**Table 2.** Consistent ChIP-seq peaks near genes

Peak	Max PSAM score	Top 0.1%	'TGTTTAC'	Nearest gene	Description	RefSeq#	Distance to TSS	Intronic?
1	0.45	Yes	No	NFIA	Nuclear factor I/A	NM_001145512	93	
2	1.00	Yes	Yes	TPRG1L	Tumor protein p63-regulated gene 1-like protein	NM_182752	199	
3	1.00	Yes	Yes	BROX	BRO1 domain and CAAX motif containing	NM_144695	802	Intronic
4	1.00	Yes	Yes	RBM17	RNA-binding motif protein 17	NM_001145547	2444	
6	1.00	Yes	Yes	PSMA1	Proteasome subunit $\alpha$ type-1	NM_148976	64934	Intronic
7	0.05	No	No	ZBTB16	Zinc-finger and BTB domain containing 16	NM_006006	102 327	Intronic
9	0.10	Yes	No	NAB2	NGFI-A-binding protein 2 (EGR1-binding protein 2)	NM_005967	273	
10	0.22	Yes	No	TPCN1	Two pore segment channel 1	NM_001143819	1534	Intronic
11	1.00	Yes	Yes	BTG1	B-cell translocation gene 1, anti-proliferative	NM_001731	50	
13	1.00	Yes	Yes	KLHDC2	Kelch domain containing 2	NM_014315	46	
14	0.14	Yes	No	KIAA0586	Uncharacterized protein	NM_001244189	120	Intronic
15	1.00	Yes	Yes	BAHCC1	Bromo adjacent homology domain and coiled-coil containing 1	NM_001080519	5616	
16	1.00	Yes	Yes	DHX8	DEAH (Asp-Glu-Ala-His) box polypeptide 8	NM_004941	47	
17	1.00	Yes	Yes	DHX40	DEAH (Asp-Glu-Ala-His) box polypeptide 40	NM_024612	49	
18	0.04	No	No	SPOP	Speckle-type POZ protein (SPOP)	NM_001007226	99	
19	1.00	Yes	Yes	PHLPP1	PH domain leucine-rich repeat-containing protein phosphatase 1	NM_194449	216	
20	1.00	Yes	Yes	LTBP4	Latent-transforming growth factor $\beta$ -binding protein 4	NM_001042544	2595	Intronic
21	1.00	Yes	Yes	JUNB	Jun B proto-oncogene	NM_002229	149	
22	0.14	Yes	No	FBXO46	F-box protein 46	NM_001080469	5927	Intronic
23	1.00	Yes	Yes	BBC3	BCL2-binding component 3	NM_001127240	517	Intronic
24	1.00	Yes	Yes	FUZ	Fuzzy homolog ( <i>Drosophila</i> )	NM_025129	363	
25	0.14	Yes	No	SPAST	Spastin	NM_014946	115	
27	0.07	Yes	No	ARHGAP25	Rho GTPase-activating protein 25	NM_001007231	3084	
29	1.00	Yes	Yes	PCMTD2	Protein-L-isoaspartate O-methyltransferase domain-containing protein	NM_018257	5581	Intronic
32	1.00	Yes	Yes	HSF2BP	Heat shock transcription factor 2-binding protein	NM_007031	48 420	Intronic
33	1.00	Yes	Yes	PIGP	Phosphatidylinositol N-acetylglucosaminyltransferase subunit P	NM_153682	12 250	
34	1.00	Yes	Yes	C21orf77	C21orf77	NM_144659	6138	
35	1.00	Yes	Yes	CBX7	Chromobox protein homolog 7	NM_175709	6758	Intronic
36	1.00	Yes	Yes	CECR3	Cat eye syndrome chromosome region, candidate 3 (non-protein coding)	NR_038398	173	
38	1.00	Yes	Yes	FOXP1	Forkhead box P1	NM_032682	100	
39	1.00	Yes	Yes	MAML3	Mastermind-like protein 3	NM_018717	131	
40	1.00	Yes	Yes	YTHDC1	YTH domain-containing protein 1	NM_001031732	19	
41	0.14	Yes	No	UBE2B	Ubiquitin-conjugating enzyme E2B	NM_003337	74	
42	1.00	Yes	Yes	POLK	DNA-directed DNA polymerase $\kappa$	NM_016218	10 564	Intronic
43	1.00	Yes	Yes	NR3C1	Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)	NM_000176	47 709	Intronic
44	0.01	No	No	GPANK1	G patch domain and ankyrin repeats 1	NM_001199237	346	
46	1.00	Yes	Yes	CCDC28A	Coiled-coil domain containing 28A	NM_015439	236	
47	0.14	Yes	No	FAM8A1	Family with sequence similarity 8, member A1	NM_016255	6	
48	0.45	Yes	No	DTNBP1	Dystrobrevin-binding protein 1	NM_032122	110 549	Intronic
49	1.00	Yes	Yes	RUNX2	Runt-related transcription factor 2	NM_004348	23 847	Intronic
50	1.00	Yes	Yes	CITED2	Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2	NM_006079	869	
51	0.00	No	No	PRKRIP1	PRKR interacting protein 1 (IL11 inducible)	NM_024653	157	
52	1.00	Yes	Yes	ELN	Elastin	NM_000501	15 646	Intronic
53	1.00	Yes	Yes	CBLL1	Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1	NM_024814	205	
54 & 55	1.00	Yes	Yes	FOXP2	Forkhead box P2	NR_033766.1	84	
56	1.00	Yes	Yes	FOXP1	Forkhead box K1	NM_001037165	62 596	Intronic

(continued)



**Table 2.** Continued

Peak	Max PSAM score	Top 0.1%	'TGTTTAC'	Nearest gene	Description	RefSeq#	Distance to TSS	Intronic?
57	1.00	Yes	Yes	HIBADH	3-hydroxyisobutyrate dehydrogenase	NM_152740	140	
58	1.00	Yes	Yes	THSD7A	Thrombospondin type-1 domain-containing protein 7A	NM_015204	291 190	Intronic
59	1.00	Yes	Yes	TNRC18	Trinucleotide repeat-containing gene 18 protein	NM_001080495	459	
61	1.00	Yes	Yes	PVT1	Pvt1 oncogene (non-protein coding)	NR_003367	57 522	Intronic
62	1.00	Yes	Yes	ZNF395	Zinc-finger protein 395	NM_018660	15 465	
63	0.05	No	No	FNTA	Farnesyltransferase, CAAX box, $\alpha$	NM_002027	37	
64	1.00	Yes	Yes	OSR2	Protein odd-skipped-related 2	NM_001142462	77	
65	0.22	Yes	No	TNFRSF10B	Tumor necrosis factor (ligand) superfamily, member 10	NM_003810	34	
66	0.45	Yes	No	FBXO32	F-box protein 32	NM_058229	79	
67	0.14	Yes	No	ASAP1	ArfGAP with SH3 domain, ankyrin repeat and PH domain 1	NM_018482	5653	Intronic
69	1.00	Yes	Yes	BRD3	Bromodomain containing 3	NM_007371	32	
70	0.50	Yes	No	TBL1X	Transducin ( $\beta$ )-like 1X-linked	NM_005647	159	

Peaks within 5 kb of either end of a gene model are shown along with PSAM motif scores. Max PSAM score refers to the maximum local alignment score. If the PSAM score is in the top 0.1% of score for random 7mers then it is noted in the 'Top 0.1%' column. The 'TGTTTAC' column notes whether the peak contains the consensus TGTTTAC. Nearest Gene, description and RefSeq# characterize the gene model nearest each peak. The nucleotide distance to TSS is sometimes >5 kb because some peaks are downstream of the gene model, and some are within large introns, as noted in the last column (intergenic peaks are described in [Supplementary Table S6](#)).

**Table 3.** Gene ontology term analysis of consistent peaks from the ENCODE ChIP-seq data, with number of genes in each category noted


Cell line	GO #	GO term	P-value	No. of genes
PFSK-1	0008134	Transcription factor binding	0.0016	54
PFSK-1	0030528	Transcription regulator activity	0.0016	83
SK-N-MC	0003690	Double-stranded DNA binding	0.0558	6
SK-N-MC	0003700	Sequence-specific DNA-binding transcription factor activity	0.0470	23
SK-N-MC	0016563	Transcription activator activity	0.0558	13
SK-N-MC	0016564	Transcription repressor activity	0.0189	13

salient and suggests that there is a set of conserved target sites for FOXP2 throughout vertebrates.

Human-specific exceptions to this generally strong conservation at the binding site could provide insight into FOXP2's function in human-specific phenotypes. Therefore, we sought to identify particular FOXP2-binding targets with poorly conserved binding sites among the 71 high-confidence target loci. The sites near *HSF2BP* and *PCMTD2* localization peaks contain instances of our strongest binding sequence that are unique to the human lineage. HSF2BP (heat shock factor 2-binding protein) is known to bind the developmental transcription factor HSF2, which is required for normal brain development (40,41). A single base change in humans was responsible for creating a new strong binding site in the seventh intron of HSF2BP. PCMTD2 (protein-L-isoaspartate O-methyltransferase domain containing 2) is an aspartate and asparagine repair enzyme, and mice lacking this enzyme have increased brain size, abnormal arborization of pyramidal neuron dendrites and die early of progressive epilepsy (42,43). In the second intron of *PCMTD2*, an 18-bp deletion created a new strong FOXP2-binding site. These examples sparked our interest in the *cis* evolution of FOXP2-binding sites.

To conduct a broader survey of strong FOXP2 *cis*-regulatory binding sites that may be evolutionarily novel, we investigated ChIP-seq peaks that were consistently identified within either the PFSK-1 or SK-N-MC cell lines and contained perfect matches to the strongest binding sequence. We found 38 instances of changes in sequence between chimp and human resulting in strong binding sites within replicate ChIP-seq sites. Of these, we discarded 16 sites in which the chimp sequence alone seemed to have acquired mutations relative to the mammalian consensus, leaving 22 sites of interest (Table 4). Roughly half of these events involve an insertion or deletion and the rest involve one or more point mutations. In all, 63% (10/16) of the nearby genes have brain-specific functions (annotated in gray in Table 4) and several may have direct roles in neuronal function.

For example, we find sites near the genes encoding gap junction protein delta 2 (*GJD2*), consorin (*C1orf71*) and neuronal calcium sensor 1 (*NCS1*), both of which are involved in neuronal signal transduction. *GJD2* forms a class of electrical synapses that modulate the firing pattern of neurons during development (44,45), and gap junction assembly requires consorin (46). At chemical synapses, *NCS1* modifies synaptic activity in response to calcium



**Figure 5.** Conservation of sequences within ChIP-seq peaks containing instances of the FOXP2 motif. (A) Example of two FOXP2 ChIP-seq peaks aligned with elements of strong conservation upstream of *BACCHI* on Chr17: 79 366 750–79 370 250 (hg18 / NCBI36). Alignments are shown for two high-confidence peak regions with high scoring instances of our MEME motif, and the vertebrate conservation score for the underlying sequence. (B) The mean of the phastcons conservation score over the FOXP2 peak regions is displayed relative to the position of the strong FOXP2-binding motif, with the genomic background average conservation score in red. The first principal component of the phastcons conservation is plotted in blue on the same scale, noted on the right-hand axis.

current, with broader roles in plasticity and spatial memory tasks in mice (47,48). These candidate novel target genes could have been important to the evolution of the FOXP2 regulon in humans.

## DISCUSSION

An accurate and precise binding site model provides a useful tool to study FOXP2's evolution and molecular involvement in the development of language. Despite intense interest, the true binding preferences of FOXP2 have remained a mystery, with different experimental techniques yielding different candidate consensus sites (Table 1). To clarify FOXP2's binding site preference, we produced detailed models of the binding site from independent microfluidic affinity cell free assays (Figure 3) and neuronal cell-based ChIP-seq data sets (Figure 4). We find that the human and chimp FOXP2 *in vitro* binding profiles are virtually identical, featuring the same degeneracies at the same positions. The *in vitro* MITOMI

data provide additional information about the penalties of a given substitution, whereas the ChIP-seq data provide clues to genomic targets in a more physiological setting. Using our *in vitro* derived motif to identify candidate FOXP2-binding sites, we find 18 ChIP-seq peaks with binding sites that would have been missed by a strict 'TG TTTAC' consensus sequence search. We identify several human-specific FOXP2-binding sites that may contribute to the evolutionarily novel role of FOXP2 in language.

In addition to the strong similarity between our independently derived motifs, other observations suggest that we have identified a relevant FOXP2-binding motif. First, our motif is consistent with the accepted RYMAAYA non-FOXP Forkhead box family theme (49,50). Second, conservation scores within ChIP-seq peak regions tend to peak at the exact location of our predicted binding sites. Together, these independent lines of evidence suggest that we have resolved the functional FOXP2-binding motif, modeled both in terms of positional affinity effects and positional frequencies among bound sites.

**Table 4.** FOXp2-binding sites within ChIP-seq peaks where the human sequence is novel relative to chimps and other primates

Peak location	Human TFBS	Human TFBS bits	Chimp TFBS	Chimp TFBS bits	Change type	Cell type	Relative to nearest gene	Nearest gene	Description
Chr1:232878698–232878854	GTAACA	13.63	CGTGAC	3.86	SNP or SNPs	PFSK-1	Sixth intron	Clorf71	Consortin, connexin sorting protein
Chr1:244869749–244869890	GTAACA	13.63		0.00	Ins/Del > 50 bp	PFSK-1			
Chr10:12150643–12150783	GTAACA	13.63	GTGAACA	5.79	SNP or SNPs	PFSK-1	182-bp upstream	DHTKD1	Dehydrogenase E1 and transketolase domain containing 1
Chr10:1272357–1272503	TGTTTAC	13.63		0.00	Ins/Del > 50 bp	PFSK-1	Fifth intron	ADARB2	Adenosine deaminase, RNA-specific, B2
Chr10:42453548–42453718	GTAACA	13.63	GGCAACA	3.14	Partial Ins/Del	PFSK-1	First intron	ZNF33B	Zinc-finger protein 33B
Chr12:68922880–68923112	GTAACA	13.63	GTAATA	9.25	SNP or SNPs	PFSK-1	94-bp upstream of the start	CNOT2	CCR4-NOT transcription complex, subunit 2
Chr15:32832867–32833011	TGTTTAC	13.63	TGTTTAG	5.64	SNP or SNPs	PFSK-1	First Intron	GJD2	Gap junction protein, Δ 2, 36 kDa
Chr17:31916541–31916693	GTAACA	13.63	GTAAACA	5.79	SNP or SNPs	PFSK-1	46 bp from the start	ZNHIT3	Zinc-finger, HIT-type containing 3
Chr18:72193002–72193148	TGTTTAC	13.63	TATTTAG	1.67	SNP or SNPs	PFSK-1			
Chr18:9063758–9063905	TGTTTAC	13.63	TATTTAC	9.25	SNP or SNPs	SK-N-MC			
Chr19:18263776–18263918	GTAACA	13.63		0.00	Ins/Del > 50 bp	PFSK-1			
Chr2:179910111–179910256	TGTTTAC	13.63	TGTTTTC	9.86	SNP or SNPs	SK-N-MC			
Chr2:197174993–197175140	TGTTTAC	13.63	TGTCTAC	5.68	SNP or SNPs	PFSK-1			
Chr2:203161760–203161908	TGTTTAC	13.63		0.00	Ins/Del > 50 bp	SK-N-MC			
Chr2:236168933–236169074	GTAACA	13.63	ATAAACA	8.85	SNP or SNPs	SK-N-MC	First intron	AGAPI	Centaurin, γ 2 isoform 1
Chr20:62362996–62363143	GTAACA	13.63	CTAAACA	5.64	Partial Ins/Del	SK-N-MC	Second intron	PCMTD2	Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2
Chr21:43854041–43854198	GTAACA	13.63	CTAAACA	5.64	SNP or SNPs	SK-N-MC	Seventh intron	HSF2BP	Heat shock transcription factor 2 binding
Chr21:46942689–46942846	GTAACA	13.63		0.00	Ins/Del > 50 bp	PFSK-1			
Chr5:4755263–4755405	TGTTTAC	13.63	TATTTAC	9.25	Partial Ins/Del	PFSK-1			
Chr6:164362950–164363091	TGTTTAC	13.63	CGTTTAC	7.51	SNP or SNPs	SK-N-MC			
Chr7:882304–882459	TGTTTAC	13.63		0.00	Ins/Del > 50 bp	PFSK-1	1 kb downstream	UNC84A	Unc-84 homolog A
Chr9:132039295–132039457	TGTTTAC	13.63	TGTTTCC	5.72	SNP or SNPs	PFSK-1	Last exon	NCS1	Neuronal calcium sensor 1

Coordinates listed are relative to Hg18/NCBI36 draft of the human genome. Nearest gene models within 5 kb of these peaks are noted, with the blank spaces signifying that there is no gene model within 5 kb of the peak. The motif values are given in bits for alignment of the site in question to the 7mer human MEME matrix; only those sites with the highest possible 7mer motif value (13.63 bits) are displayed. Gray shading denotes a gene with brain-specific function.

Additional analysis demonstrates that the motif derived here improves consistency with previous FOXP2 ChIP-chip data (17). Our core motif, modeled as a 5mer TGTKK for the sake of comparison, is overrepresented in the most significant ChIP probes, whereas the previously suggested ATTTG motif is present at the level of expectation (Supplementary Figure S9). Nucleotide biases can complicate motif search algorithms and may explain some of the previous controversy surrounding the binding site. There is a G/C bias in the most highly enriched ChIP-chip probes, perhaps because of a tendency for FOXP2 to bind sites near TSSs within CpG islands (51).

Encouragingly, orthologs of the genes we identify as likely binding targets of FOXP2 also have altered patterns of expression and Foxp2 ChIP-chip signal as shown in previous experiments. Vernes *et al.* (52) profiled expression in wild-type and Foxp2 321X mutant mice and returned a list of 19 genes that had both ChIP-chip signal and significant expression changes. We found that 17 of these 19 genes have a peak within 5kb in at least one sample in the human ENCODE ChIP-seq data; *ALCAM*, *CCK*, *CSDE1*, *EBF2*, *GNAL*, *GNAS*, *MAPK8IP3*, *MAST1*, *NEGR1*, *NRN1*, *PLAG1*, *PSME4*, *SFXN4*, *TCF12*, *TGFBI*, *CITED2* and *COL24A1*. An especially interesting target candidate from this list is *CITED2* (Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2), which modulates recruitment of the p300 histone acetyltransferase to promoters resulting in remodeling of the chromatin locus (53) and modification of FOXO proteins (54). *CITED2* and these other genes seem to be reproducible FOXP2 targets as observed by independent researchers, with both activating and repressing outcomes (52).

From the ENCODE ChIP-seq data, we produced lists of consistent localization targets in neuronal cell lines and found that FOXP2 binds near genes encoding DNA-binding proteins, such as glucocorticoid receptor and other forkhead box proteins. The set of putative targets includes an alternative transcript of *FOXP2* itself and the gene encoding its annotated binding partner *FOXPI*. The ChIP-seq association with *FOXPI* is interesting because disruptions of these genes produce phenotypes with similar characteristics (55) and can cooperatively regulate reporter constructs (36,56). We speculate that autoregulation of the FOXP2 circuit may prove important to FOXP2's developmental function. In support of this hypothesis, FOXP2 is thought to be part of a co-expressed network of genes having a higher degree of connectivity in humans than in chimp and macaque (57). These themes are consistent with the idea of FOXP2 as a regulator of transcriptional regulators.

Regarding the question of FOXP2's functional evolution, our data suggest that some of the genomic binding sites have evolved, while the DNA-binding specificity of FOXP2 has been conserved. The FOXP2 PSAM motif and binding sites show a high degree of conservation in both biochemical affinity measurements and sequence alignment at ChIP-seq peaks. This pattern of broad target site conservation suggests that there is a core set of FOXP2 targets in vertebrates, with a limited but interesting set of changed targets in humans. We have observed

22 potential examples of such *cis* evolution. These may represent newly acquired regulatory targets for human FOXP2 (Table 4, e.g. *NCS1* a synaptic calcium sensor involved in synaptic plasticity). Importantly, the FOXP2 bound genes listed here should not be considered an authoritative list. Rather, they were primarily used to analyze the binding site, and candidate binding sites were investigated for potential instances of evolution in humans. However, with a comprehensive binding site model, we can now improve our lists of direct FOXP2 targets and better understand how its regulon may have changed over evolution. Future work of interest may include investigation of the differential protein-protein interactions of the chimp and human FOXP2, and generation of chimp FOXP2 ChIP-seq data for comparison with the existing mouse and human data sets.

## SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online: Supplementary Tables 1–8 and Supplementary Figures 1–9.

## ACKNOWLEDGEMENTS

The authors would like to acknowledge Simone Marticke, the Myers Laboratory and ENCODE for public deposition of the ChIP-seq peak data; the Biomolecular Nanotechnology Center at UC Berkeley; and the QB3 Nanofab and Center for Advanced Technology (CAT) at UCSF for equipment support.

## FUNDING

Howard Hughes Medical Institute (to C.N., A.G., J.D.R. and P.F.); QB3 California Institute for Quantitative Biosciences (to C.N., J.D.R. and P.F.); Helen Hay Whitney Foundation (to P.F.). Funding for open access charge: Howard Hughes Medical Institute. H.L. and C.F. are funded by NIH-NIGMS [5R01GM070808-08].

*Conflict of interest statement.* None declared.

## REFERENCES

- Scharff, C. and Petri, J. (2011) Evo-devo, deep homology and FoxP2: implications for the evolution of speech and language. *Philos. Trans. R Soc. Lond. B Biol. Sci.*, **366**, 2124–2140.
- Lai, C.S., Fisher, S.E., Hurst, J.A., Vargha-Khadem, F. and Monaco, A.P. (2001) A forkhead-domain gene is mutated in a severe speech and language disorder. *Nature*, **413**, 519–523.
- Fisher, S.E., Vargha-Khadem, F., Watkins, K.E., Monaco, A.P. and Pembrey, M.E. (1998) Localisation of a gene implicated in a severe speech and language disorder. *Nat. Genet.*, **18**, 168–170.
- Stroud, J.C., Wu, Y., Bates, D.L., Han, A., Nowick, K., Paabo, S., Tong, H. and Chen, L. (2006) Structure of the forkhead domain of FOXP2 bound to DNA. *Structure*, **14**, 159–166.
- Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A.D., Stroud, J.C., Bates, D.L., Guo, L., Han, A., Ziegler, S.F. *et al.* (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT. *Cell*, **126**, 375–387.
- Shu, W., Yang, H., Zhang, L., Lu, M.M. and Morrissey, E.E. (2001) Characterization of a new subfamily of winged-helix/forkhead



- (Fox) genes that are expressed in the lung and act as transcriptional repressors. *J. Biol. Chem.*, **276**, 27488–27497.
7. MacDermot, K.D., Bonora, E., Sykes, N., Coupe, A.M., Lai, C.S.L., Vernes, S.C., Vargha-Khadem, F., McKenzie, F., Smith, R.L., Monaco, A.P. *et al.* (2005) Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits. *Am. J. Hum. Genet.*, **76**, 1074–1080.
  8. Hurst, J.A., Baraitser, M., Auger, E., Graham, F. and Norell, S. (1990) An extended family with a dominantly inherited speech disorder. *Dev. Med. Child. Neurol.*, **32**, 352–355.
  9. Zhang, J., Webb, D.M. and Podlaha, O. (2002) Accelerated protein evolution and origins of human-specific features: Foxp2 as an example. *Genetics*, **162**, 1825–1835.
  10. Enard, W., Przeworski, M., Fisher, S.E., Lai, C.S.L., Wiebe, V., Kitano, T., Monaco, A.P. and Pääbo, S. (2002) Molecular evolution of FOXP2, a gene involved in speech and language. *Nature*, **418**, 869–872.
  11. Yu, F., Keinan, A., Chen, H., Ferland, R.J., Hill, R.S., Mignault, A.A., Walsh, C.A. and Reich, D. (2009) Detecting natural selection by empirical comparison to random regions of the genome. *Hum. Mol. Genet.*, **18**, 4853–4867.
  12. Shu, W., Cho, J.Y., Jiang, Y., Zhang, M., Weisz, D., Elder, G.A., Schmeidler, J., De Gasperi, R., Sosa, M.A.G., Rabidou, D. *et al.* (2005) Altered ultrasonic vocalization in mice with a disruption in the Foxp2 gene. *Proc. Natl Acad. Sci. USA*, **102**, 9643–9648.
  13. Haesler, S., Rochefort, C., Georgi, B., Licznarski, P., Osten, P. and Scharff, C. (2007) Incomplete and inaccurate vocal imitation after knockdown of FoxP2 in songbird basal ganglia nucleus Area X. *PLoS Biol.*, **5**, e321.
  14. Enard, W., Gehre, S., Hammerschmidt, K., Hölter, S.M., Blass, T., Somel, M., Brückner, M.K., Schreiweis, C., Winter, C., Sohr, R. *et al.* (2009) A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. *Cell*, **137**, 961–971.
  15. Schubert, L.A., Jeffery, E., Zhang, Y., Ramsdell, F. and Ziegler, S.F. (2001) Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. *J. Biol. Chem.*, **276**, 37672–37679.
  16. Wang, B., Lin, D., Li, C. and Tucker, P. (2003) Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional repressors. *J. Biol. Chem.*, **278**, 24259–24268.
  17. Vernes, S.C., Spiteri, E., Nicod, J., Groszer, M., Taylor, J.M., Davies, K.E., Geschwind, D.H. and Fisher, S.E. (2007) High-throughput analysis of promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in speech and language disorders. *Am. J. Hum. Genet.*, **81**, 1232–1250.
  18. Maerkl, S.J. and Quake, S.R. (2007) A systems approach to measuring the binding energy landscapes of transcription factors. *Science*, **315**, 233–237.
  19. Fordyce, P.M., Gerber, D., Tran, D., Zheng, J., Li, H., DeRisi, J.L. and Quake, S.R. (2010) De novo identification and biophysical characterization of transcription-factor binding sites with microfluidic affinity analysis. *Nat. Biotechnol.*, **28**, 970–975.
  20. Edelheit, O., Hanukoglu, A. and Hanukoglu, I. (2009) Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies. *BMC Biotechnol.*, **9**, 61.
  21. Vernes, S.C., Nicod, J., Elahi, F.M., Coventry, J.A., Kenny, N., Coupe, A.M., Bird, L.E., Davies, K.E. and Fisher, S.E. (2006) Functional genetic analysis of mutations implicated in a human speech and language disorder. *Hum. Mol. Genet.*, **15**, 3154–3167.
  22. Khare, S.D., Ding, F., Gwanmesia, K.N. and Dokholyan, N.V. (2005) Molecular origin of polyglutamine aggregation in neurodegenerative diseases. *PLoS Comput. Biol.*, **1**, 230–235.
  23. Ross, C.A. (2002) Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. *Neuron*, **35**, 819–822.
  24. Fordyce, P.M., Pincus, D., Kimmig, P., Nelson, C.S., El-Samad, H., Walter, P. and DeRisi, J.L. (2012) Basic leucine zipper transcription factor Hc1 binds DNA in two distinct modes as revealed by microfluidic analyses. *Proc. Natl Acad. Sci. USA*, **109**, E3084–E3093.
  25. Mintseris, J. and Eisen, M.B. (2006) Design of a combinatorial DNA microarray for protein-DNA interaction studies. *BMC Bioinformatics*, **7**, 429.
  26. Wu, R.Z., Chaivorapol, C., Zheng, J., Li, H. and Liang, S. (2007) fREDUCE: detection of degenerate regulatory elements using correlation with expression. *BMC Bioinformatics*, **8**, 399.
  27. Foat, B.C., Morozov, A.V. and Bussemaker, H.J. (2006) Statistical mechanical modeling of genome-wide transcription factor occupancy data by MatrixREDUCE. *Bioinformatics*, **22**, e141–e149.
  28. Marticke, S. (2008) *Ultra-high Throughput Sequencing Analysis of Foxp2 Occupancy In the Human Genome*, Doctoral Thesis. Stanford University. Retrieved from Proquest. <http://proquest.umi.com/pqdweb?RQT=305&attempt=1&skip=1&SQ=STYPE%28dissertation%29+AND+ISBN%289780549847847%29&cf=1> (2 April 2013, date last accessed).
  29. Valouev, A., Johnson, D.S., Sundquist, A., Medina, C., Anton, E., Batzoglou, S., Myers, R.M. and Sidow, A. (2008) Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. *Nat. Methods*, **5**, 829–834.
  30. Hochberg, Y. and Benjamini, Y. (1990) More powerful procedures for multiple significance testing. *Stat. Med.*, **9**, 811–818.
  31. Bailey, T.L. and Elkan, C. (1995) The value of prior knowledge in discovering motifs with MEME. *Proc. Int. Conf. Intell. Syst. Mol. Biol.*, **3**, 21–29.
  32. Gordon, D.B., Nekudova, L., McCallum, S. and Fraenkel, E. (2005) TAMO: a flexible, object-oriented framework for analyzing transcriptional regulation using DNA-sequence motifs. *Bioinformatics*, **21**, 3164–3165.
  33. Schroeder, D.I. and Myers, R.M. (2008) Multiple transcription start sites for FOXP2 with varying cellular specificities. *Gene*, **413**, 42–48.
  34. Schneider, T.D., Stormo, G.D., Gold, L. and Ehrenfeucht, A. (1986) Information content of binding sites on nucleotide sequences. *J. Mol. Biol.*, **188**, 415–431.
  35. Chokas, A.L., Trivedi, C.M., Lu, M.M., Tucker, P.W., Li, S., Epstein, J.A. and Morrisey, E.E. (2010) Foxp1/2/4-NuRD interactions regulate gene expression and epithelial injury response in the lung via regulation of interleukin-6. *J. Biol. Chem.*, **285**, 13304–13313.
  36. Li, S., Weidenfeld, J. and Morrisey, E.E. (2004) Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. *Mol. Cell. Biol.*, **24**, 809–822.
  37. Yang, Z., Hikosaka, K., Sharkar, M.T.K., Tamakoshi, T., Chandra, A., Wang, B., Itakura, T., Xue, X., Uezato, T., Kimura, W. *et al.* (2010) The mouse forkhead gene Foxp2 modulates expression of the lung genes. *Life Sci.*, **87**, 17–25.
  38. Pollard, K.S., Hubisz, M.J., Rosenbloom, K.R. and Siepel, A. (2009) Detection of nonneutral substitution rates on mammalian phylogenies. *Genome Res.*, **20**, 110–121.
  39. Siepel, A., Bejerano, G., Pedersen, J.S., Hinrichs, A.S., Hou, M., Rosenbloom, K., Clawson, H., Spieth, J., Hillier, L.W., Richards, S. *et al.* (2005) Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. *Genome Res.*, **15**, 1034–1050.
  40. Yoshida, T., Yura, T. and Yanagi, H. (1998) Novel testis-specific protein that interacts with heat shock factor 2. *Gene*, **214**, 139–146.
  41. Kallio, M., Chang, Y., Manuel, M., Alastalo, T.-P., Rallu, M., Gitton, Y., Pirkkala, L., Loones, M.-T., Paslaru, L., Larney, S. *et al.* (2002) Brain abnormalities, defective meiotic chromosome synapsis and female subfertility in HSF2 null mice. *EMBO J.*, **21**, 2591–2601.
  42. Kim, E., Lowenson, J.D., MacLaren, D.C., Clarke, S. and Young, S.G. (1997) Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. *Proc. Natl Acad. Sci USA*, **94**, 6132–6137.
  43. Yamamoto, A., Takagi, H., Kitamura, D., Tatsuoka, H., Nakano, H., Kawano, H., Kuroyanagi, H., Yahagi, Y., Kobayashi, S., Koizumi, K. *et al.* (1998) Deficiency in protein L-isoaspartyl methyltransferase results in a fatal progressive epilepsy. *J. Neurosci.*, **18**, 2063–2074.
  44. Bennett, M.V.L. and Zukin, R.S. (2004) Electrical coupling and neuronal synchronization in the Mammalian brain. *Neuron*, **41**, 495–511.

45. Blankenship, A.G., Hamby, A.M., Firl, A., Vyas, S., Maxeiner, S., Willecke, K. and Feller, M.B. (2011) The role of neuronal connexins 36 and 45 in shaping spontaneous firing patterns in the developing retina. *J. Neurosci.*, **31**, 9998–10008.
46. Del Castillo, F.J., Cohen-Salmon, M., Charollais, A., Caille, D., Lampe, P.D., Chavrier, P., Meda, P. and Petit, C. (2009) Consortin, a trans-Golgi network cargo receptor for the plasma membrane targeting and recycling of connexins. *Hum. Mol. Genet.*, **19**, 262–275.
47. Saab, B.J., Georgiou, J., Nath, A., Lee, F.J.S., Wang, M., Michalon, A., Liu, F., Mansuy, I.M. and Roder, J.C. (2009) NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory. *Neuron*, **63**, 643–656.
48. Yip, P.K., Wong, L.F., Sears, T.A., Yáñez-Muñoz, R.J. and McMahon, S.B. (2010) Cortical overexpression of neuronal calcium sensor-1 induces functional plasticity in spinal cord following unilateral pyramidal tract injury in rat. *PLoS Biol.*, **8**, e1000399.
49. Pierrou, S., Hellqvist, M., Samuelsson, L., Enerbäck, S. and Carlsson, P. (1994) Cloning and characterization of seven human forkhead proteins: binding site specificity and DNA bending. *EMBO J.*, **13**, 5002–5012.
50. Nirula, A., Moore, D.J. and Gaynor, R.B. (1997) Constitutive binding of the transcription factor interleukin-2 (IL-2) enhancer binding factor to the IL-2 promoter. *J. Biol. Chem.*, **272**, 7736–7745.
51. Gardiner-Garden, M. and Frommer, M. (1987) CpG islands in vertebrate genomes. *J. Mol. Biol.*, **196**, 261–282.
52. Vernes, S.C., Oliver, P.L., Spiteri, E., Lockstone, H.E., Puliyadi, R., Taylor, J.M., Ho, J., Mombereau, C., Brewer, A., Lowy, E. *et al.* (2011) Foxp2 regulates gene networks implicated in neurite outgrowth in the developing brain. *PLoS Genet.*, **7**, e1002145.
53. Bhattacharya, S., Michels, C.L., Leung, M.K., Arany, Z.P., Kung, A.L. and Livingston, D.M. (1999) Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. *Genes Dev.*, **13**, 64–75.
54. Barthel, A., Schmoll, D. and Unterman, T.G. (2005) FoxO proteins in insulin action and metabolism. *Trends Endocrinol. Metab.*, **16**, 183–189.
55. Bacon, C. and Rappold, G.A. (2012) The distinct and overlapping phenotypic spectra of FOXP1 and FOXP2 in cognitive disorders. *Hum. Genet.*, **131**, 1687–1698.
56. Shu, W., Lu, M.M., Zhang, Y., Tucker, P.W., Zhou, D. and Morrisey, E.E. (2007) Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. *Development*, **134**, 1991–2000.
57. Konopka, G., Friedrich, T., Davis-Turak, J., Winden, K., Oldham, M.C., Gao, F., Chen, L., Wang, G.-Z., Luo, R., Preuss, T.M. *et al.* (2012) Human-specific transcriptional networks in the brain. *Neuron*, **75**, 601–617.